Should Patients With Cancer Receive Anticoagulants in the Absence of Established VTE to Improve Survival?
Recommendation 5.1. Anticoagulants are not recommended to improve survival in patients with cancer without VTE.
Recommendation 5.2. Patients with cancer should be encouraged to participate in clinical trials designed to evaluate anticoagulant therapy as an adjunct to standard anticancer therapies.
Clinical Question 6
What is Known About Risk Prediction and Awareness of VTE Among Patients With Cancer?
Recommendation 6.1. Based on consensus, the Panel recommends that patients with cancer be assessed for VTE risk at the time of chemotherapy initiation and periodically thereafter. Individual risk factors, including biomarkers and cancer site, do not reliably identify patients with cancer at high risk of VTE. In the outpatient setting, risk assessment can be conducted based on a validated risk assessment tool ( Reference lists from seminal articles, guidelines from other organizations, and recent review articles were hand searched for additional citations. The Update Committee reviewed the list of included reports for completeness. Subject headings and keywords used in the efficacy literature search included four major categories: venous thromboembolism (VTE), anticoagulation, malignancy, and randomized controlled trials (RCTs). The full search string is available in the Data Supplement of the original guideline document (see the "Availability of Companion Documents" field). The risk literature search also included four major categories: risk assessment, VTE, cancer, and cohort studies.
Inclusion and Exclusion Criteria
Articles for the efficacy systematic review were selected for inclusion if they were RCTs or systematic reviews of RCTs that assessed the efficacy and safety of anticoagulation in patients with cancer and included at least 50 patients per arm. Only data from conference proceedings available as full presentations or posters were included. For the risk systematic review, studies from the ambulatory setting that either developed or validated risk models were included. Only reports that included multivariate analyses were eligible. Risk assessment models limited to single cancer types were excluded. Eligible reports for both reviews were preliminarily identified after the literature search. Full-text copies were obtained to further assess eligibility. Articles that met eligibility for the efficacy search underwent data extraction by American Society of Clinical Oncology (ASCO) staff for study design and quality, patient characteristics, outcomes, and adverse events. Outcomes of interest included symptomatic and asymptomatic thrombotic events found on screening, major and minor bleeding, early and overall mortality, sudden death, and adverse events. For the risk review, data extraction included study characteristics, quality, and risk assessment model development and evaluation. Outcomes of interest included factors incorporated into the risk assessment model, model equation, and outcomes according to risk.
Evidence summary tables (Data Supplement of the original guideline document, [see the "Availability of Companion Documents" field]) were reviewed for accuracy and completeness by an ASCO staff member who was not involved in data extraction. Disagreements were resolved through discussion; the Steering Committee was consulted if necessary.
Study Quality
Trial characteristics from the randomized controlled trials (RCTs) were extracted to evaluate the potential for bias. Study quality was also assessed for the reports in the risk systematic review.
Methods Used to Formulate the Recommendations Expert Consensus

Description of Methods Used to Formulate the Recommendations
The American Society of Clinical Oncology (ASCO) first published an evidence-based clinical practice guideline on prophylaxis and treatment of venous thromboembolism (VTE) in 2007. ASCO guidelines are updated at intervals determined by an Up-date Committee; this is a full guideline update. Table 1 in the original guideline document provides a summary of the 2007 and 2012 guideline recommendations.
An Update Committee was formed to review data published since the initial guideline and update recommendations, as warranted, considering evidence identified by the systematic review.
The Update Committee met in July 2012 and had a second meeting via teleconference. During those meetings, the Update Committee reviewed evidence identified by the systematic review and revised guideline recommendations. Additional work on the guideline was completed electronically. The steering committee and lead ASCO staff person prepared an updated guideline to share with the Update Committee members for review.
Rating Scheme for the Strength of the Recommendations Not applicable
Cost Analysis A formal cost analysis was not performed and published cost analyses were not reviewed.
Method of Guideline Validation
Internal Peer Review
Description of Method of Guideline Validation
As per standard practice, the guideline was submitted to Journal of Clinical Oncology for review. The Venous Thromboembolism (VTE) Update Committee and the ASCO Clinical Practice Guideline Committee reviewed and approved this guideline document before publication.
Evidence Supporting the Recommendations Type of Evidence Supporting the Recommendations
The type of evidence supporting the recommendations is not specifically stated.
In general, the evidence was limited to randomized controlled trials (RCTs) and systematic reviews (with or without meta-analyses). Active major, serious, or potentially life-threatening bleeding not reversible with medical or surgical intervention, including but not limited to any active bleeding in a critical site (i.e., intracranial, pericardial, retroperitoneal, intraocular, intra-articular, intraspinal) Severe, uncontrolled malignant hypertension Severe, uncompensated coagulopathy (e.g., liver failure) Severe platelet dysfunction or inherited bleeding disorder Persistent, severe thrombocytopenia (<20,000/µL) Surgery or invasive procedure, including but not limited to lumbar puncture, spinal anesthesia, and epidural catheter placement Preference or refusal Nonadherence to dosing schedule, follow-up or monitoring *These criteria are specific for therapeutic doses of anticoagulation and should not be applied to prophylactic doses of anticoagulation. †Absolute contraindications are situations in which anticoagulation should not be administered because the risk of harm associated with bleeding is likely to exceed the potential benefit from anticoagulation. ‡Relative contraindications are situations in which anticoagulation may be administered if the risk of recurrent or progressive thrombosis is estimated to exceed the risk of bleeding.
Qualifying Statements Qualifying Statements
The practice guideline is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients and may not reflect the most recent evidence. This guideline does not recommend any particular product or course of medical treatment. Use of the practice guideline is voluntary. Additional information is available at the American Society of Clinical Oncology (ASCO) Web site .
Study Quality and Limitations of the Literature
Publications identified by the systematic review varied with respect to potential for bias, ranging from low to high. A majority of the trials were of moderate quality. Specific quality issues are discussed within the section for the relevant clinical question.
Implementation of the Guideline Description of Implementation Strategy
For information on the American Society for Clinical Oncology (ASCO) implementation strategy, please see the ASCO Web site .
